Claire Thomas - GlaxoSmithKline Plc Senior Vice President - Human Resources
GSKN Stock | MXN 655.00 51.98 7.35% |
President
Ms. Claire Thomas is Senior Vice President Human Resources of GlaxoSmithKline PLC., since May 2008. She was appointed to CET as Senior Vice President, Human Resources in 2008. Claire joined the company in 1996 as Senior Manager, Human Resources, Sales and Marketing Group, UK Pharmaceuticals before becoming Director of Human Resources for UK Pharmaceuticals in 1997. She was appointed Senior Vice President, Human Resources, Pharmaceuticals Europe in 2001, and Senior Vice President, Human Resources, Pharmaceuticals International in 2006. Prior to GSK, she worked for Ford Motor Company, holding various positions in Human Resources. Claire has a BS degree in Economics, Management and Industrial Relations from the University of Wales. since 2008.
Tenure | 16 years |
Phone | 44 20 8047 5000 |
Web | https://www.gsk.com |
GlaxoSmithKline Plc Management Efficiency
The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GlaxoSmithKline Plc's management efficiency ratios could be used to measure how well GlaxoSmithKline Plc manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | PRESIDENT Age | ||
Robert Falzon | Prudential Financial | 58 | |
Tammy Romo | Southwest Airlines | 61 | |
Joseph Payne | Air Transport Services | 59 | |
Stacey Goodman | Prudential Financial | 60 | |
Joyce Magrini | Burlington Stores | 62 | |
Timothy Harris | Prudential Financial | 57 | |
Pamela Harrison | Genworth Financial | 52 | |
Candace Woods | Prudential Financial | 57 | |
Jason Eaton | Southwest Airlines | N/A | |
William Payne | Air Transport Services | 53 | |
Richard Lambert | Prudential Financial | 59 | |
Ann Kappler | Prudential Financial | N/A | |
Robert Jordan | Southwest Airlines | 62 | |
Michael Ven | Southwest Airlines | 61 | |
Kenneth Tanji | Prudential Financial | 57 | |
Michael Laming | Genworth Financial | 64 | |
Scott McKay | Genworth Financial | 54 | |
Mark Shaw | Southwest Airlines | 55 | |
Rick Seeger | Burlington Stores | 53 | |
Janet Dhillon | Burlington Stores | 53 | |
Gregory Wells | Southwest Airlines | 59 |
Management Performance
Return On Equity | 0.31 | |||
Return On Asset | 0.0659 |
GlaxoSmithKline plc Leadership Team
Elected by the shareholders, the GlaxoSmithKline Plc's board of directors comprises two types of representatives: GlaxoSmithKline Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline Plc's management team and ensure that shareholders' interests are well served. GlaxoSmithKline Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Vindi Banga, Senior Independent Non-Executive Director | ||
Lynn Elsenhans, Independent Non-Executive Director | ||
Luke Miels, President - Global Pharmaceuticals | ||
Hal Barron, Chief Scientific Officer and Presidentident - R&D, Executive Director | ||
Daniel Podolsky, Non-Executive Independent Director | ||
Emma Walmsley, President - Consumer Healthcare Worldwide | ||
Luc Debruyne, President - Global Vaccines | ||
Andrew Witty, CEO, Executive Director | ||
Brian McNamara, CEO - GSK Consumer Healthcare | ||
Roy Anderson, Non-Executive Independent Director | ||
Philip Hampton, Independent Non-Executive Director | ||
Simon Dingemans, CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
Vivienne Cox, Non-Executive Director | ||
Bill Louv, Senior Vice President - Core Business Services | ||
Diana Conrad, Chief Officer | ||
Roger Connor, President - Global Manufacturing & Supply | ||
Abbas Hussain, President Global Pharmaceuticals | ||
Phil Thomson, Senior Vice President - Global Communications | ||
Judy Lewent, Non-Executive Independent Director | ||
Hans Wijers, Independent Non-Executive Director | ||
Shobie Ramakrishnan, Chief Officer | ||
Sarah EltonFarr, Head Relations | ||
Stephanie Burns, Non-Executive Independent Director | ||
Julie Brown, Chief Officer | ||
Moncef Slaoui, Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee | ||
Urs Rohner, Non-Executive Independent Director | ||
Marvinder Banga, Senior Non-Executive Independent Director | ||
Deryck Maughan, Senior Independent Non-Executive Director | ||
Jesse Goodman, Non-Executive Director | ||
Laurie Glimcher, Non-Executive Director | ||
Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
Sally Jackson, VP Office | ||
James Ford, Sr Compliance | ||
Victoria Whyte, Company Secretary | ||
Daniel Troy, Sr. VP and General Counsel | ||
Shah Hussain, President - Europe, Japan & EMAP | ||
Tony Wood, Chief Officer | ||
Manvinder Banga, Non-Executive Director | ||
David Redfern, Chief Strategy Officer | ||
Patrick Vallance, President - Pharmaceuticals R&D | ||
Stacey Cartwright, Non-Executive Independent Director | ||
Regis Simard, President - Pharmaceutical Supply Chain | ||
Iain Mackay, CFO - Designate, Executive Director | ||
Karenann Terrell, Chief Digital & Technology Officer | ||
Claire Thomas, Senior Vice President - Human Resources |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.31 | |||
Return On Asset | 0.0659 | |||
Profit Margin | 0.51 % | |||
Operating Margin | 0.25 % | |||
Current Valuation | 1.79 T | |||
Shares Outstanding | 2.05 B | |||
Shares Owned By Insiders | 0.02 % | |||
Shares Owned By Institutions | 14.10 % | |||
Price To Earning | 11.33 X | |||
Price To Book | 6.05 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |